AVISE® MTX Test from Exagen Supports Horizon Therapeutics plc Clinical Trial to Evaluate Pegloticase with Methotrexate to En...
October 24 2019 - 8:20AM
Exagen Inc. (Nasdaq: XGN), is pleased to announce clinical
study support for Horizon Therapeutics plc (Nasdaq: HZNP) to
measure methotrexate polyglutamates (MTXPGs), the active
metabolites of methotrexate (MTX) in the MIRROR Randomized
Controlled Trial (RCT) Study. This study,
Methotrexate to
Increase
Response
Rates in Patients with
Uncontrolled G
Out
Receiving
pegloticase, will enroll approximately 135 subjects to evaluate the
use of methotrexate as an immunomodulator to meaningfully attenuate
an immune response to pegloticase in adults living with
uncontrolled gout. Many biologics have an improved response rate
when they are administered together with methotrexate, which
reduces the formation of anti-drug antibodies.
Ron Rocca, Chief Executive Officer at Exagen
stated, “This agreement adds to our initiative to build strong
alliances with significant pharmaceutical organizations that are
developing therapeutics with a profound impact on disease. Every
day information from our testing is being used by physicians to aid
in the diagnosis, prognosis and monitoring of patients suffering
from inflammatory and autoimmune diseases and AVISE MTX, with its
easy AVISE Touch finger stick collection method, is just one of
ways we help doctors optimize patient care. By utilizing our
state-of-the-art laboratory and patented AVISE tests to support
trials and product development, we are advancing our commitment to
be patient focused and discovery driven.”
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for
patients suffering from debilitating and chronic autoimmune
diseases by enabling timely differential diagnosis and optimizing
therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE brand, several of which are based on our proprietary
Cell-Bound Complement Activation Products, or CB-CAPs, technology.
Exagen’s goal is to enable rheumatologists to improve care for
patients through the differential diagnosis, prognosis and
monitoring of complex autoimmune and autoimmune-related diseases,
including SLE and rheumatoid arthritis. Exagen’s laboratory testing
facility is CAP accredited, CLIA certified.
Forward-Looking Statements
Exagen cautions you that statements in this press release that
are not a description of historical facts are forward-looking
statements. These statements are based on the Company's current
beliefs and expectations. Such forward-looking statements include,
but are not limited to, statements regarding the results of these
clinical utility studies validating the AVISE MTX test and the
potential to lead to increased adoption of the AVISE MTX test. The
inclusion of forward-looking statements should not be regarded as a
representation by Exagen that any of its plans will be achieved.
Actual results may differ from those set forth in this press
release due to the risks and uncertainties inherent in Exagen’s
business, including, without limitation: Exagen’s commercial
success depends upon attaining and maintaining significant market
acceptance of its testing products and promoted therapeutics among
rheumatologists, patients, third-party payers and others in the
medical community; if third-party payers do not provide coverage
and adequate reimbursement for Exagen’s testing products, or they
breach, rescind or modify their contracts or reimbursement policies
or delay payments for its testing products or promoted
therapeutics, or if Exagen or its partners are unable to
successfully negotiate payer contracts, Exagen’s commercial success
could be compromised; and other risks described in the Company’s
prior press releases and in the Company’s filings with the
Securities and Exchange Commission, including under the heading
"Risk Factors" in the Company’s Registration Statement on Form S-1
and any subsequent filings with the SEC. You are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof, and we undertake no obligation to
revise or update this press release to reflect events or
circumstances after the date hereof. All forward-looking statements
are qualified in their entirety by this cautionary statement, which
is made under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995.
CONTACTS:
Westwicke Partners Mike
CavanaughMike.Cavanaugh@westwicke.com646.677.1838 Exagen Inc. Brian
McEvillybmcevilly@exagen.com760.560.1506
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Sep 2023 to Sep 2024